| Literature DB >> 34943653 |
Alyzza Marie B Calayag1, Kenneth W Widmer2, Windell L Rivera1.
Abstract
Salmonella enterica is known as one of the most common foodborne pathogens worldwide. While salmonellosis is usually self-limiting, severe infections may require antimicrobial therapy. However, increasing resistance of Salmonella to antimicrobials, particularly fluoroquinolones and cephalosporins, is of utmost concern. The present study aimed to investigate the antimicrobial susceptibility of S. enterica isolated from pork, the major product in Philippine livestock production. Our results show that both the qnrS and the blaTEM antimicrobial resistance genes were present in 61.2% of the isolates. While qnrA (12.9%) and qnrB (39.3%) were found less frequently, co-carriage of blaTEM and one to three qnr subtypes was observed in 45.5% of the isolates. Co-carriage of blaTEM and blaCTX-M was also observed in 3.9% of the isolates. Antimicrobial susceptibility testing revealed that the majority of isolates were non-susceptible to ampicillin and trimethoprim/sulfamethoxazole, and 13.5% of the isolates were multidrug-resistant (MDR). MDR isolates belonged to either O:3,10, O:4, or an unidentified serogroup. High numbers of S. enterica carrying antimicrobial resistance genes (ARG), specifically the presence of isolates co-carrying resistance to both β-lactams and fluoroquinolones, raise a concern on antimicrobial use in the Philippine hog industry and on possible transmission of ARG to other bacteria.Entities:
Keywords: Salmonella enterica; antimicrobial resistance; bla; extended-spectrum β-lactamase; qnr
Year: 2021 PMID: 34943653 PMCID: PMC8698178 DOI: 10.3390/antibiotics10121442
Source DB: PubMed Journal: Antibiotics (Basel) ISSN: 2079-6382
Molecular characterization of S. enterica isolates.
| Serogroup | First-Phase Flagellar (H1) Antigens | Sdf I | Other | ||||
|---|---|---|---|---|---|---|---|
| H:d | H: e,h | H:g | H:i | H:r | |||
| O:3,10 ( | 39 | 23 | 7 | ||||
| O:4 ( | 1 | 2 | 25 | 1 | 9 | ||
| O:7 ( | 2 | 27 | 9 | 10 | 6 | ||
| O:8 ( | 2 | 1 | |||||
| O:9 ( | 3 | ||||||
| Other ( | |||||||
No isolates under group O:2 were detected.
Non-susceptibility levels of 178 S. enterica isolates against different antimicrobial agents.
| Class | Antimicrobial | % Non-Susceptibility |
|---|---|---|
| Penicillin | Ampicillin | 71.9% (±8.8) |
| Penicillin/β-lactamase inhibitor | Amoxicillin/clavulanic acid | 10.1% (±5.9) |
| Antipseudomonal penicillin/β-lactamase inhibitor | Piperacillin/tazobactam | 0.6% (±1.5) |
| Extended-spectrum cephalosporin | Ceftazidime | 8.4% (+5.4) |
| Ceftriaxone | 7.9% (±5.3) | |
| Cefepime | 0.0% (±0) | |
| Carbapenem | Ertapenem | 0.0% (±0) |
| Imipenem | 1.7% (±2.5) | |
| Meropenem | 0.0% (±0) | |
| Fluoroquinolone | Ciprofloxacin | 15.7% (±7.1) |
| Folate pathway inhibitor | Trimethoprim/sulfamethoxazole | 70.8% (±8.9) |
Antimicrobials classified into categories based on recommendations of Magiorakos et al. [24]. Non-susceptibility to non-ESCs, cephamycins, and aminoglycosides are not shown as these antimicrobial agents are not clinically effective, although they may appear active in vitro. Values in parenthesis are ± 95% binomial confidence intervals.
Multidrug resistance patterns of 24 S. enterica isolates.
| Number of | Multidrug Resistance Pattern 1 |
|---|---|
| 1 | Pen, Pen/BI, APen/BI, ESC, Flu |
| 14 | Pen, Pen/BI, FPI, ESC |
| 1 | Pen, Pen/BI, FPI, Car |
| 1 | Pen, Pen/BI, Car, Flu |
| 7 | Pen, FPI, Flu |
1 Pen, penicillin; Pen/BI, penicillin/β-lactamase inhibitor; APen/BI; antipseudomonal penicillin/β-lactamase inhibitor; ESC, extended-spectrum cephalosporin; Flu, fluoroquinolone; FPI, folate pathway inhibitor; Car, carbapenem.
Figure 1S. enterica isolates carrying resistance genes. Horizontal bar graphs show the total number of isolates carrying a particular antimicrobial resistance gene (ARG); vertical bar graphs show the number of isolates carrying one or more ARG. Figure was generated using UpSetR [25].
Targets and primers used in molecular characterization of S. enterica.
| Target | Nucleotide Sequence (5′-3′) | Amplicon Length (bp) | Reference |
|---|---|---|---|
| O:4 | F: GGCTTCCGGCTTTATTGG | 561 | [ |
| O:9 | F: GAGGAAGGGAAATGAAGCTTTT | 615 | [ |
| O:2, O:9 | F: CTTGCTATGGAAGACATAACGAACC | 258 | [ |
| O:6,7 | F: ATTTGCCCAGTTCGGTTTG | 341 | [ |
| O:8 | F: CGTCCTATAACCGAGCCAAC | 397 | [ |
| O:3, 10 | F: GATAGCAACGTTCGGAAATTC | 281 | [ |
| Sense60 | F: GCAGATCAACTCTCAGACCCTGGG | [ | |
| H:r | R: AAGTGACTTTTCCATCGGCTG | 275 | [ |
| H:i | R: ATAGCCATCTTTACCAGTTCC | 250 | [ |
| H:e,h | R: AACGAAAGCGTAGCAGACAAG | 200 | [ |
| H:b | R: CGCACCAGTCYWACCTAAGGCGG | 150 | [ |
| H:d | F: CCCGAAAGAAACTGCTGTAACCG | 100 | [ |
| G complex alleles (H:g) | F: GTGATCTGAAATCCAGCTTCAAG | 500 | [ |
| Sdf I | F: TGTGTTTTATCTGATGCAAGAGG | 333 | [ |
Resistance gene targets and primers used in the present study.
| Target Gene | Nucleotide Sequence (5′-3′) | Amplicon Length (bp) | Reference |
|---|---|---|---|
|
| F: ATGCGTTATATTCGCCTGTG | 747 | [ |
| R: TGCTTTGTTATTCGGGCCAA | |||
|
| F: TCGCCGCATACACTATTCTCAGAAT GA | 445 | [ |
| R: ACGCTCACCGGCTCCAGATTTAT | |||
|
| F: ATGTGCAGYACCAGTAARGTKATGG C | 593 | [ |
| R: TGGGTRAARTARGTSACCAGAAYCA GCGG | |||
|
| F: AAAAATCACTGCGCCAGTTC | 415 | [ |
| R: AGCTTATTCATCGCCACGTT | |||
|
| F: CGATATCGTTGGTGGTRCCAT | 404 | [ |
| R: CGTTAACGGCACGATGAC | |||
|
| F: CAAAGAGAGTGCAACGGATG | 205 | [ |
| R: ATTGGAAAGCGTTCATCACC | |||
|
| F: AACCCACGATGTGGGTAGC | [ | |
|
| R: TCGCGTTAAGCGGATGATGC | 666 | |
|
| R: GCACGATGACATTCGGG | 327 | |
|
| F: AGAGGATTTCTCACGCCAGG | 580 | [ |
| R: TGCCAGGCACAGATCTTGAC | |||
|
| F: GGAATAGAAATTCGCCACTG | 264 | [ |
| R: TTTGCTGTTCGCCAGTCGAA | |||
|
| F: GCAAGTTCATTGAACAGGGT | 428 | [ |
| R: TCTAAACCGTCGAGTTCGGCG |